StatSure Diagnostic Systems, Inc. (SSUR) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
StatSure Diagnostic Systems, Inc. (SSUR) trades at $0.0002. StatSure Diagnostic Systems, Inc. specializes in developing, manufacturing, and marketing rapid in-vitro assays for infectious diseases. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for SSUR: SSUR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SSUR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on SSUR.
How is this calculated? →StatSure Diagnostic Systems, Inc. (SSUR) Healthcare & Pipeline Overview
StatSure Diagnostic Systems, Inc. develops and markets rapid in-vitro diagnostic assays, focusing on infectious diseases like HIV. The company's single-use tests cater to a global market, positioning it within the competitive medical devices sector, though its small size presents unique challenges.
What Is the Investment Thesis for SSUR?
StatSure Diagnostic Systems, Inc. presents a focused investment opportunity within the rapid diagnostic assay market. Key value drivers include the continued global demand for HIV testing and the potential for expansion into other infectious disease diagnostics. However, the company's small market capitalization and limited resources pose significant risks. Growth catalysts include potential partnerships for distribution and new product development. A beta of -1.42 suggests the stock moves inversely to the market, which may be attractive to some investors. Investors should carefully consider the illiquidity and risks associated with OTC-listed companies before investing.
Based on FMP financials and quantitative analysis
SSUR Key Highlights
StatSure Diagnostic Systems, Inc. specializes in rapid in-vitro assays for infectious diseases, particularly HIV 1/2.
- The company's primary products are single-use diagnostic tests, offering a convenient solution for visual detection of antibodies.
- StatSure provides medical specimen collection devices, complementing its diagnostic test offerings.
- Founded in 1986, the company has a long-standing presence in the diagnostic testing market.
- The company operates both in the United States and internationally, expanding its market reach.
Who Are SSUR's Competitors?
SSUR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $2.96 | -1.66% | $19.3M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.3M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SSUR's Key Strengths?
Specialized expertise in rapid HIV testing.
- Established brand recognition for SURE CHECK and Clearview products.
- Existing distribution network in key markets.
- Focus on single-use, point-of-care testing solutions.
What Are SSUR's Weaknesses?
Small company size with limited resources.
- Dependence on a limited product portfolio (primarily HIV testing).
- OTC listing may limit access to capital.
- Limited R&D capabilities compared to larger competitors.
What Could Drive SSUR Stock Higher?
Potential partnerships for expanded distribution of HIV testing products.
- Development and launch of new diagnostic assays for other infectious diseases.
- Increasing global demand for rapid HIV testing solutions.
What Are the Key Risks for SSUR?
Competition from larger diagnostic companies with greater resources.
- Changes in HIV testing guidelines or reimbursement policies.
- Limited financial resources and small company size.
- Risks associated with OTC listing, including limited liquidity and disclosure.
What Are the Growth Opportunities for SSUR?
- Expansion into New Geographic Markets: StatSure can pursue growth by expanding its distribution network into underserved geographic markets with high HIV prevalence. This includes regions in Africa and Asia, where access to rapid HIV testing is limited. Successful expansion could significantly increase revenue, tapping into a market projected to grow as global health initiatives prioritize HIV prevention and treatment. The timeline for this expansion depends on securing partnerships with local distributors and obtaining regulatory approvals.
- Development of New Diagnostic Assays: StatSure can leverage its expertise in rapid assay development to create new diagnostic tests for other infectious diseases. This diversification would reduce reliance on HIV testing alone and open up new revenue streams. Potential targets include tests for STIs, respiratory infections, and emerging viral threats. The timeline for new product development depends on R&D investment and regulatory approval processes, potentially yielding new products within 2-3 years.
- Strategic Partnerships and Collaborations: StatSure can pursue strategic partnerships with larger diagnostic companies or healthcare providers to expand its market reach and access new technologies. Collaborations could involve joint development of new assays, co-marketing agreements, or distribution partnerships. These partnerships could accelerate growth and enhance StatSure's competitive position. The timeline for securing partnerships depends on negotiation and due diligence processes.
- Focus on Point-of-Care Testing (POCT): The increasing demand for point-of-care testing presents a significant growth opportunity for StatSure. By developing and marketing assays suitable for POCT settings, such as clinics, pharmacies, and remote healthcare facilities, StatSure can cater to the growing need for rapid and convenient diagnostic solutions. This requires adapting existing assays for ease of use and portability, potentially increasing market share within 2-3 years.
- Leveraging Telehealth and Digital Health Solutions: Integrating StatSure's diagnostic tests with telehealth platforms and digital health solutions can enhance accessibility and convenience for patients. This could involve developing smartphone-based readers for test results or integrating test ordering and result delivery into existing telehealth apps. By embracing digital health technologies, StatSure can cater to the evolving needs of healthcare consumers and expand its market reach. Implementation could begin within the next year, with full integration over the following 2 years.
What Threats Does SSUR Face?
- Competition from larger diagnostic companies with broader product portfolios.
- Changes in HIV testing guidelines or reimbursement policies.
- Emergence of new diagnostic technologies.
- Regulatory hurdles and compliance requirements.
What Are SSUR's Competitive Advantages?
- Specialized focus on rapid HIV testing.
- Established presence in the diagnostic testing market since 1986.
- Proprietary assay formulations.
- Distribution network in key geographic markets.
What Does SSUR Do?
StatSure Diagnostic Systems, Inc., founded in 1986 and based in Brooklyn, New York, develops, manufactures, and markets rapid in-vitro assays. These assays are primarily used for the detection of infectious diseases and other conditions. The company's flagship products include the SURE CHECK HIV 1/2 and Clearview Complete HIV 1/2 tests, both of which are single-use diagnostic tests designed for the visual detection of antibodies to HIV 1 and HIV 2. Additionally, StatSure provides medical specimen collection devices, complementing its diagnostic offerings. The company operates both in the United States and internationally, aiming to provide accessible and rapid diagnostic solutions. With a small team of four employees, StatSure navigates the competitive landscape of the medical devices industry, focusing on niche areas within infectious disease diagnostics.
What Products and Services Does SSUR Offer?
- Develops rapid in-vitro assays for infectious diseases.
- Manufactures diagnostic tests for visual detection of antibodies.
- Markets its products internationally.
- Offers single-use diagnostic tests for HIV 1/2.
- Provides medical specimen collection devices.
- Focuses on point-of-care testing solutions.
How Does SSUR Make Money?
- Develops and manufactures rapid diagnostic tests.
- Sells diagnostic tests and collection devices to healthcare providers and distributors.
- Generates revenue through direct sales and distribution agreements.
What Industry Does SSUR Operate In?
StatSure Diagnostic Systems, Inc. operates within the medical devices industry, specifically focusing on in-vitro diagnostics. The global in-vitro diagnostics market is projected to reach significant growth in the coming years, driven by increasing prevalence of infectious diseases and advancements in diagnostic technologies. The competitive landscape includes larger players with broader product portfolios, as well as smaller, niche-focused companies. StatSure's focus on rapid HIV testing positions it in a specific segment of this market, where speed and ease of use are key differentiators.
Who Are SSUR's Key Customers?
- Hospitals and clinics
- Laboratories
- Healthcare providers
- International distributors
- Point-of-care testing facilities
Company Profile
StatSure Diagnostic Systems, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Brooklyn, US. The company is led by CEO Moshe Bodner. SSUR has traded publicly since 1994.
SSUR Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that management believes in the growth potential.
- Social sentiment has shifted positively, with many community discussions highlighting innovative product developments that could capture market share.
- Analysts have noted the company’s strategic partnerships, which may enhance its distribution capabilities and broaden its customer base.
- There’s a growing demand for diagnostic solutions, and StatSure's advancements align well with industry trends, positioning it favorably.
Bear Case
- Concerns over competition have emerged, as rival firms are also advancing their diagnostic technologies, potentially impacting StatSure's market position.
- Recent community sentiment has shown some skepticism regarding the scalability of their operations, raising questions about future profitability.
- Insider selling activity has raised red flags for some investors, suggesting that those closest to the company may be hedging their bets.
- Market perception has been mixed, with some analysts cautioning about the company's ability to navigate regulatory challenges in the diagnostic space.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SSUR Latest News
No recent news available for SSUR.
SSUR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SSUR.
Price Targets
Wall Street price target analysis for SSUR.
SSUR MoonshotScore
What does this score mean?
The MoonshotScore rates SSUR 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Moshe Bodner
CEO
Moshe Bodner is the CEO of StatSure Diagnostic Systems, Inc. His background includes managing the company's operations and overseeing the development, manufacturing, and marketing of its rapid in-vitro assays. He has been instrumental in guiding the company's focus on infectious disease diagnostics, particularly HIV testing. His leadership is crucial in navigating the competitive landscape of the medical devices industry.
Track Record: Under Moshe Bodner's leadership, StatSure Diagnostic Systems, Inc. has maintained its focus on providing rapid HIV testing solutions. Key achievements include the continued marketing of SURE CHECK HIV 1/2 and Clearview Complete HIV 1/2 tests. His strategic decisions have centered on maintaining a niche market position within the infectious disease diagnostics sector.
SSUR OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that StatSure Diagnostic Systems, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This can lead to increased risks for investors due to the potential for less transparency and information availability.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's financial statements and disclosures.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Monitor trading volume and price volatility.
- Consult with a qualified financial advisor.
- Understand the risks associated with OTC investing.
- Long-standing presence in the diagnostic testing market (founded in 1986).
- Focus on providing rapid HIV testing solutions.
- Existing distribution network in key markets.
- Development and marketing of proprietary diagnostic tests.
StatSure Diagnostic Systems, Inc. Healthcare Stock: Key Questions Answered
What does StatSure Diagnostic Systems, Inc. do?
StatSure Diagnostic Systems, Inc. develops, manufactures, and markets rapid in-vitro assays, primarily focusing on the detection of infectious diseases. Their main products are the SURE CHECK HIV 1/2 and Clearview Complete HIV 1/2 tests, which are single-use diagnostic tests for the visual detection of antibodies to HIV 1 and HIV 2. Additionally, they provide medical specimen collection devices.
What do analysts say about SSUR stock?
As of 2026-03-16, there is no available analyst coverage or consensus on StatSure Diagnostic Systems, Inc. (SSUR) due to its OTC listing and small market capitalization. Investors should conduct their own due diligence and consider the risks associated with investing in thinly traded, micro-cap stocks. Key valuation metrics are not readily available, and growth considerations should be assessed based on the company's financial disclosures and market opportunities.
What are the main risks for SSUR?
The main risks for StatSure Diagnostic Systems, Inc. include its small size and limited financial resources, which may hinder its ability to compete with larger diagnostic companies. The company's dependence on a limited product portfolio (primarily HIV testing) also poses a risk. Additionally, the OTC listing presents risks related to liquidity, disclosure, and regulatory oversight.
What are the key factors to evaluate for SSUR?
Evaluate SSUR on fundamentals, analyst consensus, and risk factors. StatSure Diagnostic Systems, Inc. presents a focused investment opportunity within the rapid diagnostic assay market. Not financial advice.
How frequently does SSUR data refresh on this page?
SSUR's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SSUR's recent stock price performance?
StatSure Diagnostic Systems, Inc. (SSUR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in rapid HIV testing. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SSUR overvalued or undervalued right now?
StatSure Diagnostic Systems, Inc. (SSUR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SSUR before investing?
Before investing in StatSure Diagnostic Systems, Inc. (SSUR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the company's OTC status.
- AI analysis pending for SSUR, which may provide additional insights.